75308-46-2

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 2,6-dichloroisonicotinate is used as a key intermediate in the synthesis of various drugs and pharmaceutical compounds, leveraging its diverse pharmacological properties for the development of novel therapeutic agents.
Used in Agrochemical Production:
tert-Butyl 2,6-dichloroisonicotinate is utilized as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals to protect crops and enhance agricultural productivity.
Used in Dye and Pigment Manufacturing:
Tert-Butyl 2,6-dichloroisonicotinate is employed in the manufacturing of dyes and pigments, providing a foundation for the creation of vibrant and stable colorants used in various industries, including textiles, plastics, and printing inks.
Used in Antiviral and Antibacterial Applications:
Due to its antiviral and antibacterial properties, Tert-Butyl 2,6-dichloroisonicotinate is used in the development of therapeutic agents to combat viral and bacterial infections, offering potential treatments for a range of diseases.
Used in Anti-Inflammatory Drug Development:
The anti-inflammatory properties of Tert-Butyl 2,6-dichloroisonicotinate make it a valuable component in the development of anti-inflammatory drugs, which can be used to treat various inflammatory conditions and alleviate pain and swelling.

InChI:InChI=1/C10H11Cl2NO2/c1-10(2,3)15-9(14)6-4-7(11)13-8(12)5-6/h4-5H,1-3H3

Upstream product

• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 71432-55-8 2-tert-butyl-1,3-diisopropylisourea 
• 115-11-7 isobutene 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1062671-27-5 (S)-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol 
• 1062669-94-6 (S)-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol 
• 1062671-33-3 (S)-N-(3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,3,4]oxadiazol-2-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062671-18-4 (S)-N-(3-(4-(3-(2-(diethylamino)-6-methylpyridin-4-yl)-[1,2,4]oxadiazol-5-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062670-13-6 (S)-N-(3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1062671-30-0 C₂₄H₃₃N₅O₃ 
• 1062671-19-5 4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-2-ethyl-6-methylphenol 
• 1062671-23-1 {4-[5-(4-benzyloxy-3-ethyl-5-methylphenyl)-[1,3,4]oxadiazol-2-yl]-6-methylpyridin-2-yl}diethylamine 
• 1062671-14-0 C₂₄H₃₃N₅O₃ 
• 1062671-08-2 4-[3-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-2-ethyl-6-methyl-phenol 
• 1062670-07-8 (S)-1-amino-3-(4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propan-2-ol 
• 1062670-10-3 (S)-N,N-diethyl-4-(3-(3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-6-methylpyridin-2-amine 
• 1062669-89-9 4-(5-(2-(diethylamino)-6-methylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenol 
• 857363-49-6 2,6-dimethyl-isonicotinic acid hydrochloride 

Relevant academic research and scientific papers

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

COMPOUNDS AND METHODS OF USE

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Practical and scalable synthesis of S1P1 receptor agonist ACT-209905

A practical and scalable route for the fast delivery of 12 kg of S1P 1 agonist (ACT-209905) has been developed. ACT-209905 is composed of an amino pyridine group, an oxadiazole spacer, a 2-ethyl-5-methylphenol moiety and a chiral 1-amino-2-propanol side chain. The convergent synthesis consists of 16 steps with 9 isolated intermediates and is chromatography-free. Key building blocks are accessed from low-cost starting materials, such as acetone, diethyl oxalate, cyanoacetamide, and 2-ethyl-5-methyl aniline. A Negishi coupling that was troubled by the use of metal reagents and concomitant metal waste streams has been replaced by a less expensive Guareschi-Thorpe reaction to build up an amino isonicotinic acid. The chiral 1-amino-2-propanol moiety was secured by selective ring-opening of an epoxide with lithium hexamethyldisilazide as an ammonia surrogate, thus omitting the notorious double alkylated byproduct.

PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Development of a scalable synthesis of dipeptidyl peptidase-4 inhibitor ABT-279

A convergent, scalable synthesis of dipeptidyl peptidase-4 inhibitor, ABT-279, has been developed and demonstrated on multikilogram scale. The cis-2,5-disubstituted pyrrolidine is generated by cyclization of a Boc-amine onto an alkynyl ketone followed by stereospecific reduction of the resulting acyliminium intermediate. The amine coupling partner was prepared by a novel Hofmann rearrangement promoted by 1,3-dibromo-5,5-dimethylhydantoin. The final product was isolated as the L-malic acid salt. The scaleup campaign consisted of 15 steps and delivered 42 kg of ABT-279 in 14% overall yield. A second-generation synthesis that addresses some of the issues encountered during scale-up was developed and demonstrated on kilogram scale.